FDA Clears Long-Acting ADHD Drug Mydayis

 ADHD in the News 2017-06-22

The US Food and Drug Administration (FDA) has approved a long-acting medication for attention-deficit/hyperactivity disorder (ADHD) from Shire called Mydayis (mixed salts of a single-entity amphetamine product). The once-daily treatment comprises three different types of drug-releasing beads and is formulated to last up to 16 hours. It is approved for adults and children aged 13 years and older with ADHD. Mydayis is is not for use in children aged 12 years and younger."